Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$-37 Mln
ROE
-5.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
58,783,500
CFO
$-353.94 Mln
EBITDA
$-344.39 Mln
Net Profit
$-361.91 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genocea Biosciences (GNCA)
| 100.0 | 100.0 | -98.7 | -100.0 | -95.5 | -88.0 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Genocea Biosciences (GNCA)
| -100.0 | -52.1 | 16.9 | -9.8 | -75.1 | -71.8 | -21.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genocea Biosciences (GNCA)
|
0.0 | 0.0 | 1.9 | -37.2 | -1,910.9 | -148.1 | -- | 0.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every... target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. Read more
Pres, CEO & Director
Mr. William D. Clark M.B.A.
Pres, CEO & Director
Mr. William D. Clark M.B.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Genocea Biosciences Inc (GNCA) is $0.00 (NASDAQ) as of 24-Feb-2023 09:30 EDT. Genocea Biosciences Inc (GNCA) has given a return of -95.46% in the last 3 years.
Since, TTM earnings of Genocea Biosciences Inc (GNCA) is negative, P/E ratio is not available.
The P/B ratio of Genocea Biosciences Inc (GNCA) is 0.01 times as on 24-Feb-2023, a 100 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Genocea Biosciences Inc (GNCA) are Rs -- and Rs -- as of 04-Apr-2026.
Genocea Biosciences Inc (GNCA) has a market capitalisation of $ 0 Mln as on 24-Feb-2023. As per SEBI classification, it is a company.
Before investing in Genocea Biosciences Inc (GNCA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.